Personalis at Immuno Week Europe: July 6-9, 2021
Presentation
Maik Pruess, PhD
Senior Field Application Scientist
Personalis, Inc.
Wednesday, JUL 7 | 10:50 AM BST
Advancing Biomarker Discovery: Enabling improved tumor immunogenomics through a comprehensive approach
- Predicting patient response to immunotherapies requires a robust approach to tumor immunogenomics.
- By combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT™ provides a broad view of the tumor and the immune- related components of the tumor microenvironment from a single sample preparation.
- Combination of ImmunoID NeXT and our exome-wide liquid biopsy assay, NeXT Liquid Biopsy, allows for increased exploration of critical areas of tumor biology.
Connect with us at Immuno Week Europe 2021
